Trustco Bank Corp N Y Has $2.91 Million Holdings in Johnson & Johnson (NYSE:JNJ)

Trustco Bank Corp N Y decreased its position in Johnson & Johnson (NYSE:JNJ) by 1.6% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 20,097 shares of the company’s stock after selling 330 shares during the quarter. Johnson & Johnson comprises 3.1% of Trustco Bank Corp N Y’s investment portfolio, making the stock its 9th largest holding. Trustco Bank Corp N Y’s holdings in Johnson & Johnson were worth $2,906,000 at the end of the most recent reporting period.

Several other large investors have also made changes to their positions in the company. Two Sigma Advisers LP grew its stake in shares of Johnson & Johnson by 48.1% in the 4th quarter. Two Sigma Advisers LP now owns 189,343 shares of the company’s stock valued at $27,383,000 after buying an additional 61,493 shares in the last quarter. Two Sigma Investments LP bought a new stake in shares of Johnson & Johnson in the 4th quarter valued at approximately $9,222,000. Texas Bank & Trust Co bought a new stake in shares of Johnson & Johnson in the 4th quarter valued at approximately $3,005,000. Tidal Investments LLC grew its stake in shares of Johnson & Johnson by 16.6% in the 4th quarter. Tidal Investments LLC now owns 217,795 shares of the company’s stock valued at $31,498,000 after buying an additional 30,935 shares in the last quarter. Finally, Tolleson Wealth Management Inc. bought a new stake in shares of Johnson & Johnson in the 4th quarter valued at approximately $243,000. Institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Stock Performance

Shares of NYSE JNJ opened at $151.37 on Monday. The business has a fifty day simple moving average of $156.27 and a 200 day simple moving average of $153.85. The company has a current ratio of 1.11, a quick ratio of 0.86 and a debt-to-equity ratio of 0.43. The firm has a market capitalization of $364.20 billion, a price-to-earnings ratio of 22.76, a PEG ratio of 2.56 and a beta of 0.42. Johnson & Johnson has a one year low of $140.68 and a one year high of $169.99.

Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Tuesday, April 15th. The company reported $2.77 EPS for the quarter, beating analysts’ consensus estimates of $2.59 by $0.18. The business had revenue of $21.89 billion during the quarter, compared to analyst estimates of $21.65 billion. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. Sell-side analysts expect that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, June 10th. Investors of record on Tuesday, May 27th will be paid a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a dividend yield of 3.44%. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $1.24. The ex-dividend date is Tuesday, May 27th. Johnson & Johnson’s dividend payout ratio is presently 57.84%.

Insider Activity at Johnson & Johnson

In other Johnson & Johnson news, VP Robert J. Decker sold 6,999 shares of the stock in a transaction on Tuesday, February 25th. The stock was sold at an average price of $165.88, for a total transaction of $1,160,994.12. Following the completion of the transaction, the vice president now directly owns 21,001 shares in the company, valued at $3,483,645.88. This represents a 25.00% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Timothy Schmid sold 403 shares of the stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $156.15, for a total value of $62,928.45. Following the transaction, the executive vice president now owns 15,098 shares of the company’s stock, valued at $2,357,552.70. This represents a 2.60% decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.16% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

Several brokerages recently commented on JNJ. Bank of America lowered their price target on Johnson & Johnson from $171.00 to $159.00 and set a “neutral” rating for the company in a research note on Thursday, April 10th. Leerink Partners cut Johnson & Johnson from an “outperform” rating to a “market perform” rating and decreased their target price for the stock from $169.00 to $153.00 in a research report on Tuesday, May 13th. Argus raised Johnson & Johnson to a “strong-buy” rating in a research report on Friday, January 24th. Barclays decreased their target price on Johnson & Johnson from $166.00 to $165.00 and set an “equal weight” rating for the company in a research report on Thursday, April 17th. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and set a $181.00 target price on shares of Johnson & Johnson in a research report on Wednesday, April 16th. Eleven analysts have rated the stock with a hold rating, seven have assigned a buy rating and three have issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $170.88.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.